Our Platform indications discovery

theraTRACE®
Melior Pharmaceuticals applies its theraTRACE® drug repositioning platform of multiplexed in vivo disease models to uncover new indications for existing pharmaceutical compounds. These disease models are run with full consideration of key in vivo pharmacodynamic and pharmacokinetic parameters of test compounds.

Melior's pharmacology expertise comprises more than 30 years of experience with in vivo pharmacology. Leveraging this knowledge, Melior has created its theraTRACE® platform for systematically evaluating a compound's efficacy across a large number of high quality disease models. theraTRACE® achieves this with tremendous efficiency with respect to time, test compound and number of test subjects.

Back to top of page